Media » Mylan Receives Tentative Approval for Combination HIV Treatment DTG/FTC/TAF Under FDA's PEPFAR Program

Mylan Receives Tentative Approval for Combination HIV Treatment DTG/FTC/TAF Under FDA’s PEPFAR Program

Mylan Receives Tentative Approval for Combination HIV Treatment DTG/FTC/TAF Under FDA's PEPFAR Program

Global pharmaceutical company Mylan today announced receipt of tentative approval from the U.S. Food and Drug Administration under the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application for Dolutegravir, Emtricitabine, and Tenofovir Alafenamide Tablets, 50 mg/200 mg/25 mg. The antiretroviral will be immediately available in developing countries as a first-line regimen for people being treated for HIV/AIDS.

This website uses cookies to ensure you get the best experience on our website. Learn More